| Year |
Citation |
Score |
| 2022 |
Zettlitz KA, Salazar FB, Yamada RE, Trinh KR, Vasuthasawat A, Timmerman JM, Morrison SL, Wu AM. 89Zr-ImmunoPET shows therapeutic efficacy of anti-CD20 interferon-α fusion protein in a murine B-cell lymphoma model. Molecular Cancer Therapeutics. PMID 35086952 DOI: 10.1158/1535-7163.MCT-21-0732 |
0.322 |
|
| 2020 |
Gamache RF, Zettlitz KA, Tsai WK, Collins J, Wu AM, Murphy JM. Tri-functional platform for construction of modular antibody fragments for F-PET or NIRF molecular imaging. Chemical Science. 11: 1832-1838. PMID 34123276 DOI: 10.1039/c9sc05007h |
0.323 |
|
| 2020 |
Dai H, Ma Z, Wang F, Zhong Y, Salazar F, Li J, Zhang M, Ren F, Wu AM. Advancing nanomedicine with cross-link functionalized nanoparticles for rapid excretion. Angewandte Chemie (International Ed. in English). PMID 32681553 DOI: 10.1002/Anie.202008083 |
0.351 |
|
| 2020 |
Tsai WK, Zettlitz KA, Dahlbom M, Reiter RE, Wu AM. Evaluation of [I]I- and [Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer. Molecular Imaging and Biology. PMID 32661830 DOI: 10.1007/S11307-020-01518-4 |
0.404 |
|
| 2020 |
Bäck TA, Jennbacken K, Hagberg Thulin M, Lindegren S, Jensen H, Olafsen T, Yazaki PJ, Palm S, Albertsson P, Damber JE, Wu AM, Welén K. Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. Ejnmmi Research. 10: 10. PMID 32048062 DOI: 10.1186/S13550-020-0600-Z |
0.303 |
|
| 2020 |
Akhavan D, Yazaki P, Yamauchi D, Simpson J, Frankel PH, Bading J, Colcher D, Poku K, Chen YJ, Lim D, Cristea M, Wu A, Shively J, Wong JYC. Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies. Cancer Biotherapy & Radiopharmaceuticals. PMID 31910346 DOI: 10.1089/Cbr.2019.2992 |
0.344 |
|
| 2020 |
Gamache RF, Zettlitz KA, Tsai WK, Collins J, Wu AM, Murphy JM. Tri-functional platform for construction of modular antibody fragments for in vivo18F-PET or NIRF molecular imaging Chemical Science. 11: 1832-1838. DOI: 10.1039/C9Sc05007H |
0.377 |
|
| 2019 |
Pandit-Taskar N, Postow M, Hellmann M, Harding J, Barker C, O'Donoghue J, Ziolkowska M, Ruan S, Lyashchenko S, Tsai F, Farwell M, Mitchell T, Korn R, Le W, Lewis J, ... ... Wu A, et al. First-in-human imaging with Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31586002 DOI: 10.2967/Jnumed.119.229781 |
0.374 |
|
| 2019 |
Kasten BB, Udayakumar N, Leavenworth JW, Wu AM, Lapi SE, McConathy JE, Sorace AG, Bag AK, Markert JM, Warram JM. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics. 9: 5085-5104. PMID 31410203 DOI: 10.7150/Thno.34415 |
0.333 |
|
| 2019 |
Zettlitz KA, Tsai WK, Knowles SM, Salazar FB, Kobayashi N, Reiter RE, Wu AM. [Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31209779 DOI: 10.1007/S11307-019-01386-7 |
0.345 |
|
| 2019 |
Zettlitz KA, Waldmann CM, Tsai WK, Tavaré R, Collins J, Murphy JM, Wu AM. A dual-modality linker enables site-specific conjugation of antibody fragments for F-immunoPET and fluorescence imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30877181 DOI: 10.2967/Jnumed.118.223560 |
0.444 |
|
| 2019 |
Kao RL, Truscott LC, Chiou TT, Tsai W, Wu AM, De Oliveira SN. A cetuximab-mediated suicide system in CAR-modified hematopoietic stem cells for cancer therapy. Human Gene Therapy. PMID 30860401 DOI: 10.1089/Hum.2018.180 |
0.303 |
|
| 2018 |
Tsai WK, Zettlitz KA, Tavaré R, Kobayashi N, Reiter RE, Wu AM. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody. Theranostics. 8: 5903-5914. PMID 30613270 DOI: 10.7150/Thno.27679 |
0.378 |
|
| 2018 |
Zettlitz KA, Tavaré R, Tsai WK, Yamada RE, Ha NS, Collins J, van Dam RM, Timmerman JM, Wu AM. F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice. European Journal of Nuclear Medicine and Molecular Imaging. PMID 30456475 DOI: 10.1007/S00259-018-4214-X |
0.398 |
|
| 2018 |
Zhang M, Kobayashi N, Zettlitz KA, Kono EA, Yamashiro JM, Tsai WK, Jiang ZK, Tran CP, Wang C, Guan J, Wu AM, Reiter RE. Near-infrared-dye labeled anti-Prostate Stem Cell Antigen minibody enables real-time fluorescence imaging and targeted surgery in translational mouse models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30301826 DOI: 10.1158/1078-0432.Ccr-18-1382 |
0.374 |
|
| 2018 |
Seo JW, Tavaré R, Mahakian LM, Silvestrini MT, Tam S, Ingham ES, Salazar FB, Borowsky AD, Wu AM, Ferrara KW. CD8+ T-cell density imaging with 64Cu-labeled cys-diabody informs immunotherapy protocols. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29967252 DOI: 10.1158/1078-0432.Ccr-18-0261 |
0.383 |
|
| 2018 |
Zettlitz KA, Tsai WK, Knowles SM, Kobayashi N, Donahue TR, Reiter RE, Wu AM. Dual-modality immunoPET and near-infrared fluorescence (NIRF) imaging of pancreatic cancer using an anti-prostate cancer stem cell antigen (PSCA) cys-diabody. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29602820 DOI: 10.2967/Jnumed.117.207332 |
0.426 |
|
| 2018 |
Tsai WK, Wu AM. Aligning physics and physiology: Engineering antibodies for radionuclide delivery. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 29537104 DOI: 10.1002/Jlcr.3622 |
0.415 |
|
| 2018 |
Freise AC, Zettlitz KA, Salazar FB, Tavaré R, Tsai WK, Hadjioannou A, Rozengurt N, Braun J, Wu AM. ImmunoPET in inflammatory bowel disease: Imaging CD4+ T cells in a murine model of colitis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29326360 DOI: 10.2967/Jnumed.117.199075 |
0.361 |
|
| 2018 |
Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, ... Wu AM, et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 7: e1380764. PMID 29308300 DOI: 10.1080/2162402X.2017.1380764 |
0.4 |
|
| 2018 |
Postow MA, Harding JJ, Hellmann MD, Gordon MS, Tsai F, O' Donoghue JA, Lewis JS, Wu AM, Le W, Korn RL, Weber W, Wolchok JD, Pandit-Taskar N. Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors. Journal of Clinical Oncology. 36: e24160-e24160. DOI: 10.1200/Jco.2018.36.15_Suppl.E24160 |
0.359 |
|
| 2018 |
Kono EA, Kobayashi N, Zettlitz K, Yamashiro J, Chun W, Hu DZ, Wu AM, Reiter RE. Abstract A52: Efficacy of new developed N-cadherin monoclonal antibodies in combination with enzalutamide against castration-resistant prostate cancer Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Tcm17-A52 |
0.38 |
|
| 2018 |
Parisi G, Saco J, Bergara F, Krystofinski P, Zhang R, Saus CP, Hu-Lieskovan S, Comin-Anduix B, Wu A, Charych DH, Ribas A. Abstract 3566: Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214 Cancer Research. 78: 3566-3566. DOI: 10.1158/1538-7445.Am2018-3566 |
0.346 |
|
| 2018 |
Kono EA, Kobayashi N, Zettlitz K, Li K, Yamashiro J, Wang C, Wu A, Reiter RE. Abstract 1775: Development of fully humanized N-cadherin monoclonal antibodies for treatment of castration resistant prostate cancer Cancer Research. 78: 1775-1775. DOI: 10.1158/1538-7445.Am2018-1775 |
0.384 |
|
| 2017 |
Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, Chang CH, Jiang J, Wang X, Wu AM, Meng H, Nel AE. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nature Communications. 8: 1811. PMID 29180759 DOI: 10.1038/S41467-017-01651-9 |
0.337 |
|
| 2017 |
Zettlitz KA, Tavare R, Knowles SM, Steward KK, Timmerman JM, Wu AM. ImmunoPET of malignant and normal B cells with (89)Zr- and (124)I-labeled obinutuzumab antibody fragments reveals differential CD20 internalization in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28928164 DOI: 10.1158/1078-0432.Ccr-17-0855 |
0.382 |
|
| 2017 |
Shields AF, Jacobs P, Sznol M, Graham MM, Germain R, Lum L, Jaffee E, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung D, Wu AM, Sharon E, Shankar LK. Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28818991 DOI: 10.2967/Jnumed.117.195610 |
0.377 |
|
| 2017 |
Orcutt KD, Adams GP, Wu AM, Silva MD, Harwell C, Hoppin J, Matsumura M, Kotsuma M, Greenberg J, Scott AM, Beckman RA. Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28213834 DOI: 10.1007/S11307-016-1041-Y |
0.427 |
|
| 2017 |
Tsai WK, Zettlitz KA, Tavaré R, Salazar FB, Reiter RE, Wu AM. Abstract 1856: Dual-modality immunoPET/fluorescence imaging of prostate cancer utilizing89Zr- or124I-Cy5.5-anti-PSCA cys-minibody Cancer Research. 77: 1856-1856. DOI: 10.1158/1538-7445.Am2017-1856 |
0.4 |
|
| 2016 |
Freise AC, Zettlitz KA, Salazar FB, Lu X, Tavaré R, Wu AM. ImmunoPET Imaging of Murine CD4(+) T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 27966069 DOI: 10.1007/S11307-016-1032-Z |
0.362 |
|
| 2016 |
Mayle KM, Dern KR, Wong VK, Chen KY, Sung S, Ding K, Rodriguez AR, Knowles S, Taylor Z, Zhou ZH, Grundfest WS, Wu AM, Deming TJ, Kamei DT. Engineering A11 Minibody-Conjugated, Polypeptide-Based Gold Nanoshells for Prostate Stem Cell Antigen (PSCA)-Targeted Photothermal Therapy. Journal of Laboratory Automation. PMID 27659802 DOI: 10.1177/2211068216669710 |
0.313 |
|
| 2016 |
Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko S, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, et al. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27516450 DOI: 10.2967/Jnumed.116.176206 |
0.332 |
|
| 2016 |
McCracken MN, Tavaré R, Witte ON, Wu AM. Advances in PET Detection of the Antitumor T Cell Response. Advances in Immunology. 131: 187-231. PMID 27235684 DOI: 10.1016/Bs.Ai.2016.02.004 |
0.339 |
|
| 2016 |
Morris MJ, Martinez DF, Durack JC, Slovin SF, Danila DC, O' Donoghue JA, Parada NA, Lyashchenko SK, Carrasquillo JA, Ruan S, Lewis JS, Keppler J, Wu AM, Reuter VE, Weber W, et al. A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa). Journal of Clinical Oncology. 34: 287-287. DOI: 10.1200/Jco.2016.34.2_Suppl.287 |
0.308 |
|
| 2015 |
Tavare R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, Witte ON, Ribas A, Wu AM. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Research. PMID 26573799 DOI: 10.1158/0008-5472.Can-15-1707 |
0.384 |
|
| 2015 |
Sonn GA, Behesnilian AS, Jiang ZK, Zettlitz KA, Lepin EJ, Bentolila L, Knowles SM, Lawrence DJ, Wu AM, Reiter RE. Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real-Time. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26490315 DOI: 10.1158/1078-0432.Ccr-15-0503 |
0.388 |
|
| 2015 |
Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Engineering, Design & Selection : Peds. PMID 25991864 DOI: 10.1093/Protein/Gzv024 |
0.368 |
|
| 2015 |
Tavare R, McCracken MN, Zettlitz KA, Salazar FB, Olafsen T, Witte ON, Wu AM. ImmunoPET of murine T cell reconstitution post-adoptive stem cell transplant using anti-CD4 and anti-CD8 cys-diabodies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 25952734 DOI: 10.2967/Jnumed.114.153338 |
0.332 |
|
| 2015 |
Freise AC, Wu AM. In vivo imaging with antibodies and engineered fragments. Molecular Immunology. 67: 142-52. PMID 25934435 DOI: 10.1016/J.Molimm.2015.04.001 |
0.412 |
|
| 2015 |
Watanabe R, Hanaoka H, Sato K, Nagaya T, Harada T, Mitsunaga M, Kim I, Paik CH, Wu AM, Choyke PL, Kobayashi H. Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 140-4. PMID 25500827 DOI: 10.2967/Jnumed.114.149526 |
0.408 |
|
| 2015 |
Morris MJ, Solomon SB, Durack JC, O' Donoghue JA, Lyashchenko SK, Shutian R, Carrasquillo JA, Lewis JS, Martinez DF, Parada NA, Keppler J, Wu A, Reuter VE, Weber W, Scher HI, et al. Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer. Journal of Clinical Oncology. 33: 220-220. DOI: 10.1200/Jco.2015.33.7_Suppl.220 |
0.356 |
|
| 2015 |
Tavare R, Escuin-Ordinas H, McCracken M, Zettlitz K, Salazar F, Witte O, Ribas A, Wu A. Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P391 |
0.401 |
|
| 2014 |
Oh J, Apte A, Folkerts M, Kohutek Z, Wu A, Rimmer A, Lee N, Deasy J. WE-E-17A-03: FDG-PET-Based Radiomics to Predict Local Control and Survival Following Radiotherapy. Medical Physics. 41: 507-508. PMID 28038073 DOI: 10.1118/1.4889445 |
0.336 |
|
| 2014 |
Knowles SM, Tavaré R, Zettlitz KA, Rochefort MM, Salazar FB, Jiang ZK, Reiter RE, Wu AM. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6367-78. PMID 25326233 DOI: 10.1158/1078-0432.Ccr-14-1452 |
0.34 |
|
| 2014 |
Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Molecular Cancer Therapeutics. 13: 2607-17. PMID 25143449 DOI: 10.1158/1535-7163.Mct-14-0363 |
0.401 |
|
| 2014 |
Tavaré R, Wu WH, Zettlitz KA, Salazar FB, McCabe KE, Marks JD, Wu AM. Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation. Protein Engineering, Design & Selection : Peds. 27: 317-24. PMID 25095796 DOI: 10.1093/Protein/Gzu030 |
0.389 |
|
| 2014 |
Wilks MQ, Knowles SM, Wu AM, Huang SC. Improved modeling of in vivo kinetics of slowly diffusing radiotracers for tumor imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 1539-44. PMID 24994929 DOI: 10.2967/Jnumed.114.140038 |
0.301 |
|
| 2014 |
Watanabe R, Sato K, Hanaoka H, Harada T, Nakajima T, Kim I, Paik CH, Wu AM, Choyke PL, Kobayashi H. Minibody-indocyanine green based activatable optical imaging probes: the role of short polyethylene glycol linkers. Acs Medicinal Chemistry Letters. 5: 411-5. PMID 24900850 DOI: 10.1021/Ml400533Y |
0.411 |
|
| 2014 |
Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Molecular Pharmaceutics. 11: 3965-73. PMID 24779727 DOI: 10.1021/Mp500164R |
0.452 |
|
| 2014 |
Rochefort MM, Girgis MD, Knowles SM, Ankeny JS, Salazar F, Wu AM, Tomlinson JS. A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 721-729. PMID 24691872 DOI: 10.1007/S11307-014-0733-4 |
0.455 |
|
| 2014 |
Knowles SM, Zettlitz KA, Tavaré R, Rochefort MM, Salazar FB, Stout DB, Yazaki PJ, Reiter RE, Wu AM. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 452-9. PMID 24504052 DOI: 10.2967/Jnumed.113.120873 |
0.398 |
|
| 2014 |
Williams LE, Wu AM, Kenanova VE, Olafsen T, Yazaki PJ. Numerical comparison of iodine-based and indium-based antibody biodistributions. Cancer Biotherapy & Radiopharmaceuticals. 29: 91-8. PMID 24443889 DOI: 10.1089/Cbr.2013.1564 |
0.346 |
|
| 2014 |
Tavaré R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, Witte ON, Wu AM. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proceedings of the National Academy of Sciences of the United States of America. 111: 1108-13. PMID 24390540 DOI: 10.1073/Pnas.1316922111 |
0.424 |
|
| 2014 |
Wu AM. Engineered antibodies for molecular imaging of cancer. Methods (San Diego, Calif.). 65: 139-47. PMID 24091005 DOI: 10.1016/J.Ymeth.2013.09.015 |
0.426 |
|
| 2014 |
Olafsen T, Bartlett D, Ho D, Zhang G, Torgov M, Keppler J, Behrenbruch C, Wu A, Pandit-Taskar N, Morris MJ, Lewis JS, Lyashchenko SK, Gudas JM. Minibody imaging of prostate-specific membrane antigen (PSMA): From concept to clinic. Journal of Clinical Oncology. 32: e16057-e16057. DOI: 10.1200/Jco.2014.32.15_Suppl.E16057 |
0.403 |
|
| 2014 |
Olafsen T, Ho D, Epin E, Zhang G, Torgov M, Beigarten C, Agahi G, Cabral E, Wu AM, Gudas JM. Abstract LB-163: Development of an immunoPET tracer for imaging human CD8+ T cells Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-163 |
0.403 |
|
| 2014 |
Orcutt KD, Adams GP, Wu AM, Silva M, Hoppin J, Harwell C, Matsumura M, Kotsuma M, Freeman D, Tse A, Greenberg J, Scott A, Beckman RA. Abstract 4300: Receptor occupancy and tumor penetration by antibodies, peptides, and antibody fragments: Molecular simulation of imaging assessment Cancer Research. 74: 4300-4300. DOI: 10.1158/1538-7445.Am2014-4300 |
0.442 |
|
| 2014 |
Jiang ZK, Wu A, Reiter R. Abstract 111: In search of a lead fluorescent tracer for PSCA-expressing prostate cancer: A comprehensive analysis of imaging agents and dyes Cancer Research. 74: 111-111. DOI: 10.1158/1538-7445.Am2014-111 |
0.416 |
|
| 2013 |
Widney DP, Olafsen T, Wu AM, Kitchen CM, Said JW, Smith JB, Peña G, Magpantay LI, Penichet ML, Martinez-Maza O. Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7. Plos One. 8: e72414. PMID 23936541 DOI: 10.1371/Journal.Pone.0072414 |
0.356 |
|
| 2013 |
Girgis MD, Federman N, Rochefort MM, McCabe KE, Wu AM, Nagy JO, Denny C, Tomlinson JS. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. The Journal of Surgical Research. 185: 45-55. PMID 23827791 DOI: 10.1016/J.Jss.2013.05.095 |
0.426 |
|
| 2013 |
Sano K, Nakajima T, Ali T, Bartlett DW, Wu AM, Kim I, Paik CH, Choyke PL, Kobayashi H. Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging. Journal of Biomedical Optics. 18: 101304. PMID 23752742 DOI: 10.1117/1.Jbo.18.10.101304 |
0.411 |
|
| 2013 |
Fu M, Brewer S, Olafsen T, Wu AM, Gordon LK, Said J, Braun J, Wadehra M. Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 15: 68-78. PMID 22585360 DOI: 10.1007/S11307-012-0558-Y |
0.461 |
|
| 2013 |
Leyton JV, Olafsen T, Lepin EJ, Hahm S, Fonge H, Reiter RE, Wu AM. Positron Emission Tomographic Imaging of Iodine 124 Anti–Prostate Stem Cell Antigen–Engineered Antibody Fragments in LAPC-9 Tumor–Bearing Severe Combined Immunodeficiency Mice Molecular Imaging. 12: 7290.2012.00033. DOI: 10.2310/7290.2012.00033 |
0.464 |
|
| 2013 |
Gudas J, Olafsen T, Ho D, Bartlett D, Lipman A, Sorenson K, Keppler J, Behrenbruch C, Wu A, Ashworth S, Passchier J, Gunn R, Matthews P. Abstract LB-351: Evaluation of two engineered antibody fragments derived from a human CD20 antibody as tracers for immunoPET . Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-351 |
0.431 |
|
| 2013 |
Kenanova V, Olafsen T, Wu A, Yazaki P, Williams L. SU-E-J-185: Comparison of Iodine-Labeled Sc-Fv-Fc Protein Biodistributions to Indium-Labeled Biodistributions in Nude Mice Medical Physics. 40: 194-194. DOI: 10.1118/1.4814397 |
0.352 |
|
| 2013 |
Sonn G, Lepin E, Knowles S, Zettlitz K, Wu A, Reiter R. 2027 DEVELOPMENT AND VALIDATION OF A FLUORESCENT LABELED ANTIBODY FRAGMENT FOR IMAGE-GUIDED PROSTATE CANCER SURGERY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2446 |
0.359 |
|
| 2013 |
Zhang P, Yah R, Yorke E, Hu Y, Foster A, Mageras G, Wu A, Deasy J, Rimner A. Incorporating the Prediction of Residual Tumor Location Into Prospective Dose Painting for Locally-Advanced Non-Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 87: S699. DOI: 10.1016/J.Ijrobp.2013.06.1853 |
0.302 |
|
| 2013 |
Park S, Lee JY, Hong S, Dimov IK, Li K, Wu AM, Mumenthaler S, Mallick P, Lee LP. Concurrent Transcript and Protein Quantification in a Massive Single Cell Array Enables Population-Wide Observation of Oncogene Escape Biophysical Journal. 104: 686a. DOI: 10.1016/J.Bpj.2012.11.3790 |
0.301 |
|
| 2012 |
Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3884-92. PMID 22987087 DOI: 10.1200/Jco.2012.42.4887 |
0.437 |
|
| 2012 |
Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. The Journal of Biological Chemistry. 287: 22927-37. PMID 22570488 DOI: 10.1074/Jbc.M112.355131 |
0.348 |
|
| 2012 |
Olafsen T, Sirk SJ, Olma S, Shen CK, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 33: 669-77. PMID 22392499 DOI: 10.1007/S13277-012-0365-8 |
0.773 |
|
| 2012 |
Olafsen T, Elgqvist J, Wu AM. Protein targeting constructs in alpha therapy. Current Radiopharmaceuticals. 4: 197-213. PMID 22201709 DOI: 10.2174/1874471011104030197 |
0.397 |
|
| 2012 |
McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 14: 336-47. PMID 21630083 DOI: 10.1007/S11307-011-0500-8 |
0.35 |
|
| 2011 |
Girgis MD, McCabe K, Olafsen T, Bergara F, Kenanova V, Federman N, Wu A, Tomlinson JS. An engineered anti-CA19-9 cys-diabody for PET imaging of pancreas cancer and targeting of polymerized liposomal nanoparticles. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 198. PMID 27985360 DOI: 10.1200/Jco.2011.29.4_Suppl.198 |
0.397 |
|
| 2011 |
Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. Ejnmmi Research. 1: 24. PMID 22214289 DOI: 10.1186/2191-219X-1-24 |
0.429 |
|
| 2011 |
Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. International Journal of Molecular Imaging. 2011: 834515. PMID 21912743 DOI: 10.1155/2011/834515 |
0.404 |
|
| 2011 |
Girgis MD, Kenanova V, Olafsen T, McCabe KE, Wu AM, Tomlinson JS. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. The Journal of Surgical Research. 170: 169-78. PMID 21601881 DOI: 10.1016/J.Jss.2011.03.065 |
0.429 |
|
| 2011 |
Liu K, Lepin EJ, Wang MW, Guo F, Lin WY, Chen YC, Sirk SJ, Olma S, Phelps ME, Zhao XZ, Tseng HR, Michael van Dam R, Wu AM, Shen CK. Microfluidic-based 18F-labeling of biomolecules for immuno-positron emission tomography. Molecular Imaging. 10: 168-76, 1-7. PMID 21496447 DOI: 10.2310/7290.2010.00043 |
0.738 |
|
| 2011 |
Barat B, Kenanova VE, Olafsen T, Wu AM. Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging. Molecular Imaging and Biology. 13: 526-535. PMID 20628903 DOI: 10.1007/S11307-010-0375-0 |
0.331 |
|
| 2011 |
McCabe KE, Wu AM. Positive progress in immunoPET--not just a coincidence. Cancer Biotherapy & Radiopharmaceuticals. 25: 253-61. PMID 20578830 DOI: 10.1089/Cbr.2010.0776 |
0.417 |
|
| 2011 |
Tran CP, Knowles S, Olafsen T, Lepin EJ, Wu AM, Reiter RE. Abstract 4283: Evaluation of PSCA-specific minibody for in vivo imaging Cancer Research. 71: 4283-4283. DOI: 10.1158/1538-7445.Am2011-4283 |
0.401 |
|
| 2011 |
Girgis M, Kenanova V, Olafsen T, McCabe K, Bergara F, Wu A, Tomlinson J. Anti-CA19-9 Diabody As A PET Imaging Probe For Pancreas Cancer Journal of Surgical Research. 165: 258-259. DOI: 10.1016/J.Jss.2010.11.453 |
0.33 |
|
| 2010 |
Olafsen T, Young SG, Davies BS, Beigneux AP, Kenanova VE, Voss C, Young G, Wong KP, Barnes RH, Tu Y, Weinstein MM, Nobumori C, Huang SC, Goldberg IJ, Bensadoun A, ... Wu AM, et al. Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning. The Journal of Biological Chemistry. 285: 39239-48. PMID 20889497 DOI: 10.1074/Jbc.M110.171041 |
0.315 |
|
| 2010 |
Kenanova VE, Olafsen T, Salazar FB, Williams LE, Knowles S, Wu AM. Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Engineering, Design & Selection : Peds. 23: 789-98. PMID 20802234 DOI: 10.1093/Protein/Gzq054 |
0.334 |
|
| 2010 |
Aweda TA, Beck HE, Wu AM, Wei LH, Weber WA, Meares CF. Rates and equilibria for probe capture by an antibody with infinite affinity. Bioconjugate Chemistry. 21: 784-91. PMID 20361788 DOI: 10.1021/Bc100046P |
0.329 |
|
| 2010 |
Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. European Journal of Nuclear Medicine and Molecular Imaging. 37: 1529-38. PMID 20354850 DOI: 10.1007/S00259-010-1433-1 |
0.397 |
|
| 2010 |
Olafsen T, Wu AM. Antibody vectors for imaging. Seminars in Nuclear Medicine. 40: 167-81. PMID 20350626 DOI: 10.1053/J.Semnuclmed.2009.12.005 |
0.449 |
|
| 2010 |
Sherman DJ, Kenanova VE, Lepin EJ, McCabe KE, Kamei K, Ohashi M, Wang S, Tseng HR, Wu AM, Behrenbruch CP. A differential cell capture assay for evaluating antibody interactions with cell surface targets. Analytical Biochemistry. 401: 173-81. PMID 20178770 DOI: 10.1016/J.Ab.2010.02.015 |
0.397 |
|
| 2010 |
Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, Raubitschek AA, Timmerman JM, Wu AM. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Engineering, Design & Selection : Peds. 23: 243-9. PMID 20053640 DOI: 10.1093/Protein/Gzp081 |
0.763 |
|
| 2010 |
Girgis MD, McCabe K, Federman N, Wu AM, Denny C, Tomlinson JS. Targeting cancer with cys-diabody conjugated polymerized liposomal nanoparticles (PLNs) Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-A20 |
0.434 |
|
| 2009 |
Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. Plos One. 4: e8314. PMID 20016813 DOI: 10.1371/Journal.Pone.0008314 |
0.423 |
|
| 2009 |
Afshar S, Olafsen T, Wu AM, Morrison SL. Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT. Journal of Experimental & Clinical Cancer Research : Cr. 28: 147. PMID 19958550 DOI: 10.1186/1756-9966-28-147 |
0.38 |
|
| 2009 |
Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 1500-8. PMID 19690034 DOI: 10.2967/Jnumed.108.060426 |
0.408 |
|
| 2009 |
Vaidyanathan G, Jestin E, Olafsen T, Wu AM, Zalutsky MR. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. Nuclear Medicine and Biology. 36: 671-80. PMID 19647173 DOI: 10.1016/J.Nucmedbio.2009.04.002 |
0.386 |
|
| 2009 |
Barat B, Sirk SJ, McCabe KE, Li J, Lepin EJ, Remenyi R, Koh AL, Olafsen T, Gambhir SS, Weiss S, Wu AM. Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. Bioconjugate Chemistry. 20: 1474-81. PMID 19642689 DOI: 10.1021/Bc800421F |
0.761 |
|
| 2009 |
Leyton JV, Olafsen T, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, Wu AM. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Engineering, Design & Selection : Peds. 22: 209-16. PMID 18957406 DOI: 10.1093/Protein/Gzn055 |
0.412 |
|
| 2009 |
Kenanova V, Barat B, Olafsen T, Chatziioannou A, Herschman HR, Braun J, Wu AM. Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging. 36: 104-14. PMID 18719907 DOI: 10.1007/S00259-008-0921-Z |
0.378 |
|
| 2009 |
Betting DJ, Kafi K, Yamada RE, Steward KK, Olafsen T, Wu AM, van Rooijen N, Timmerman JM. In Vivo Eradication of a Rituximab-Resistant Human CD20+ B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement. Blood. 114: 723-723. DOI: 10.1182/Blood.V114.22.723.723 |
0.403 |
|
| 2008 |
Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 2-5. PMID 19091888 DOI: 10.2967/Jnumed.108.056887 |
0.358 |
|
| 2008 |
Sirk SJ, Olafsen T, Barat B, Bauer KB, Wu AM. Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. Bioconjugate Chemistry. 19: 2527-34. PMID 19053310 DOI: 10.1021/Bc800113V |
0.749 |
|
| 2008 |
Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7488-96. PMID 19010866 DOI: 10.1158/1078-0432.Ccr-07-5093 |
0.415 |
|
| 2008 |
Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7367-77. PMID 19010852 DOI: 10.1158/1078-0432.Ccr-08-1016 |
0.384 |
|
| 2008 |
Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1828-35. PMID 18927335 DOI: 10.2967/Jnumed.108.054452 |
0.441 |
|
| 2008 |
Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer Journal (Sudbury, Mass.). 14: 191-7. PMID 18536559 DOI: 10.1097/Ppo.0B013E31817B07Ae |
0.416 |
|
| 2007 |
Venisnik KM, Olafsen T, Gambhir SS, Wu AM. Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 9: 267-77. PMID 17577599 DOI: 10.1007/S11307-007-0101-8 |
0.44 |
|
| 2007 |
Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nature Protocols. 1: 2048-60. PMID 17487194 DOI: 10.1038/Nprot.2006.322 |
0.367 |
|
| 2007 |
Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 396-405. PMID 17457214 DOI: 10.1097/Cji.0B013E318031B53B |
0.435 |
|
| 2007 |
Barat B, Wu AM. Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum. Biomolecular Engineering. 24: 283-91. PMID 17379573 DOI: 10.1016/J.Bioeng.2007.02.003 |
0.328 |
|
| 2007 |
Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Research. 67: 718-26. PMID 17234783 DOI: 10.1158/0008-5472.Can-06-0454 |
0.407 |
|
| 2006 |
Venisnik KM, Olafsen T, Loening AM, Iyer M, Gambhir SS, Wu AM. Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Engineering, Design & Selection : Peds. 19: 453-60. PMID 16882674 DOI: 10.1093/Protein/Gzl030 |
0.445 |
|
| 2006 |
Ferl GZ, Kenanova V, Wu AM, DiStefano JJ. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Molecular Cancer Therapeutics. 5: 1550-8. PMID 16818514 DOI: 10.1158/1535-7163.Mct-06-0072 |
0.412 |
|
| 2006 |
Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biotherapy & Radiopharmaceuticals. 21: 88-100. PMID 16706629 DOI: 10.1089/Cbr.2006.21.88 |
0.327 |
|
| 2006 |
Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JY, Raubitschek A, Shively JE. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjugate Chemistry. 17: 68-76. PMID 16417253 DOI: 10.1021/Bc0502614 |
0.414 |
|
| 2006 |
Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opinion On Drug Delivery. 3: 53-70. PMID 16370940 DOI: 10.1517/17425247.3.1.53 |
0.408 |
|
| 2006 |
Hurvitz SA, Betting D, Kafi-Tehrani K, Golay J, Olafsen T, Wu AM, Timmerman JM. Combination immunotherapy with rituximab and local delivery of CpG oligonucleotide in a syngeneic murine model expressing human CD20 Journal of Clinical Oncology. 24: 2502-2502. DOI: 10.1200/Jco.2006.24.18_Suppl.2502 |
0.337 |
|
| 2005 |
Ferl GZ, Wu AM, DiStefano JJ. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Annals of Biomedical Engineering. 33: 1640-52. PMID 16341929 DOI: 10.1007/S10439-011-0373-7 |
0.404 |
|
| 2005 |
Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology. 23: 1137-46. PMID 16151407 DOI: 10.1038/Nbt1141 |
0.374 |
|
| 2005 |
Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Research. 65: 5907-16. PMID 15994969 DOI: 10.1158/0008-5472.Can-04-4472 |
0.428 |
|
| 2005 |
Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Research. 65: 622-31. PMID 15695407 |
0.358 |
|
| 2005 |
Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, Sundaresan G, Wu AM, Gambhir SS, Weiss S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science (New York, N.Y.). 307: 538-44. PMID 15681376 DOI: 10.1126/Science.1104274 |
0.323 |
|
| 2005 |
Barat B, Kenanova V, Olafsen T, Wu AM. Engineered Anti-CEA Antibody Fragments and Recombinant Carcinoembryonic Antigen (CEA) As A PET Reporter System Journal of Immunotherapy. 28: 642. DOI: 10.1097/01.Cji.0000191044.76190.E5 |
0.383 |
|
| 2004 |
Yazaki PJ, Sherman MA, Shively JE, Ikle D, Williams LE, Wong JY, Colcher D, Wu AM, Raubitschek AA. Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Engineering, Design & Selection : Peds. 17: 481-9. PMID 15316127 DOI: 10.1093/Protein/Gzh056 |
0.394 |
|
| 2004 |
Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5014-21. PMID 15297402 DOI: 10.1158/1078-0432.Ccr-03-0576 |
0.43 |
|
| 2004 |
Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, Williams LE, Raubitschek AA, Press MF, Wu AM. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Engineering, Design & Selection : Peds. 17: 315-23. PMID 15187222 DOI: 10.1093/Protein/Gzh040 |
0.406 |
|
| 2004 |
Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS, Sherman MA, Williams LE, Shively JE, Raubitschek AA, Wu AM. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Engineering, Design & Selection : Peds. 17: 21-7. PMID 14985534 DOI: 10.1093/Protein/Gzh009 |
0.46 |
|
| 2004 |
Yazaki PJ, Wu AM. Expression of recombinant antibodies in mammalian cell lines. Methods in Molecular Biology (Clifton, N.J.). 248: 255-68. PMID 14970502 DOI: 10.1385/1-59259-666-5:255 |
0.323 |
|
| 2004 |
Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods in Molecular Biology (Clifton, N.J.). 248: 209-25. PMID 14970499 DOI: 10.1385/1-59259-666-5:209 |
0.364 |
|
| 2004 |
Reiter RE, Wu A, Sherman M, Gu Z. 1091: Recombinant Anti-PSCA Antibodies Inhibit Prostate and Bladder Cancer Growthin Xenograft Models and are Superior to Parental Murine Antibody Journal of Urology. 171: 287-288. DOI: 10.1016/S0022-5347(18)38328-9 |
0.353 |
|
| 2003 |
Ye JJ, Liang SJ, Guo N, Li SL, Wu AM, Giannini S, Sachdev D, Yee D, Brünner N, Ikle D, Fujita-Yamaguchi Y. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 35: 836-42. PMID 14710366 DOI: 10.1055/S-2004-814145 |
0.364 |
|
| 2003 |
Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 44: 1962-9. PMID 14660722 |
0.367 |
|
| 2003 |
Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy. 5: 131-8. PMID 12745575 DOI: 10.1080/14653240310001028 |
0.347 |
|
| 2003 |
Carmichael JA, Power BE, Garrett TP, Yazaki PJ, Shively JE, Raubischek AA, Wu AM, Hudson PJ. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. Journal of Molecular Biology. 326: 341-51. PMID 12559905 DOI: 10.1016/S0022-2836(02)01428-6 |
0.312 |
|
| 2003 |
Yazaki PJ, Wu AM. Construction and characterization of minibodies for imaging and therapy of colorectal carcinomas. Methods in Molecular Biology (Clifton, N.J.). 207: 351-64. PMID 12412485 DOI: 10.1385/1-59259-334-8:351 |
0.45 |
|
| 2002 |
Li L, Olafsen T, Anderson AL, Wu A, Raubitschek AA, Shively JE. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjugate Chemistry. 13: 985-95. PMID 12236780 DOI: 10.1021/Bc025565U |
0.338 |
|
| 2001 |
Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ, Raubitschek AA. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange Protein Engineering. 14: 1025-1033. PMID 11809933 DOI: 10.1093/Protein/14.12.1025 |
0.36 |
|
| 2001 |
Yazaki PJ, Shively L, Clark C, Cheung CW, Le W, Szpikowska B, Shively JE, Raubitschek AA, Wu AM. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. Journal of Immunological Methods. 253: 195-208. PMID 11384681 DOI: 10.1016/S0022-1759(01)00388-X |
0.403 |
|
| 2001 |
Yazaki PJ, Wu AM, Tsai SW, Williams LE, Ikler DN, Wong JY, Shively JE, Raubitschek AA. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjugate Chemistry. 12: 220-8. PMID 11312683 DOI: 10.1021/Bc000092H |
0.426 |
|
| 2001 |
Williams LE, Wu AM, Yazaki PJ, Liu A, Raubitschek AA, Shively JE, Wong JY. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biotherapy & Radiopharmaceuticals. 16: 25-35. PMID 11279795 DOI: 10.1089/108497801750095989 |
0.446 |
|
| 2000 |
Jensen MC, Clarke P, Tan G, Wright C, Chung-Chang W, Clark TN, Zhang F, Slovak ML, Wu AM, Forman SJ, Raubitschek A. Human T lymphocyte genetic modification with naked DNA. Molecular Therapy : the Journal of the American Society of Gene Therapy. 1: 49-55. PMID 10933911 DOI: 10.1006/Mthe.1999.0012 |
0.331 |
|
| 2000 |
Wu AM, Yazaki PJ, Tsai Sw, Nguyen K, Anderson AL, McCarthy DW, Welch MJ, Shively JE, Williams LE, Raubitschek AA, Wong JY, Toyokuni T, Phelps ME, Gambhir SS. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proceedings of the National Academy of Sciences of the United States of America. 97: 8495-500. PMID 10880576 DOI: 10.1073/Pnas.150228297 |
0.457 |
|
| 2000 |
Williams LE, Liu A, Wu AM, Yazaki PJ, Yamauchi DM, Lopatin G, Raubitschek AA, Wong JY. Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies. Medical Physics. 27: 988-94. PMID 10841401 DOI: 10.1118/1.598963 |
0.386 |
|
| 1998 |
Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 4: 75-83. PMID 9763110 DOI: 10.1053/Bbmt.1998.V4.Pm9763110 |
0.345 |
|
| 1997 |
Wong J, Chu D, Yamauchi D, Odom-Maryon T, Williams L, Liu A, Wilcyznski S, Wu A, Shively J, Doroshow J, Raubitschek A. 140 Phase I radioimmunotherapy trial evaluating 90Yttrium labeled anti-cea chimeric T84.66 in patients with metastatic cea-producing malignancies International Journal of Radiation Oncology*Biology*Physics. 39: 205. DOI: 10.1016/S0360-3016(97)80698-0 |
0.305 |
|
| 1996 |
Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R, Hu SZ, Odom-Maryon T, Wong JY, Shively JE. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology : An International Journal of Immunological Engineering. 2: 21-36. PMID 9373325 DOI: 10.1016/1380-2933(95)00027-5 |
0.404 |
|
| 1995 |
Williams LE, Liu A, Wu AM, Odom-Maryon T, Chai A, Raubitschek AA, Wong JY. Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Medical Physics. 22: 2025-7. PMID 8746707 DOI: 10.1118/1.597646 |
0.365 |
|
| 1992 |
Kashani-Sabet M, Funato T, Tone T, Jiao L, Wang W, Yoshida E, Kashfinn BI, Shitara T, Wu AM, Moreno JG. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Research and Development. 2: 3-15. PMID 1422085 DOI: 10.1089/Ard.1992.2.3 |
0.31 |
|
| 1981 |
Yanofsky C, Platt T, Crawford IP, Nichols BP, Christie GE, Horowitz H, VanCleemput M, Wu AM. The complete nucleotide sequence of the tryptophan operon of Escherichia coli. Nucleic Acids Research. 9: 6647-68. PMID 7038627 DOI: 10.1093/Nar/9.24.6647 |
0.704 |
|
| 1981 |
Wu AM, Christie GE, Platt T. Tandem termination sites in the tryptophan operon of Escherichia coli Proceedings of the National Academy of Sciences of the United States of America. 78: 2913-2917. PMID 6265923 DOI: 10.1073/Pnas.78.5.2913 |
0.686 |
|
| 1980 |
Wu AM, Chapman AB, Platt T, Guarente LP, Beckwith J. Deletions of distal sequence affect termination of transcription at the end of the tryptophan operon in E. coli Cell. 19: 829-836. PMID 6991123 DOI: 10.1016/0092-8674(80)90073-2 |
0.503 |
|
| 1979 |
Guarente LP, Beckwth J, Wu AM, Platt T. A mutation distal to the messenger RNA endpoint reduces transcription termination in the tryptophan operon in Escherichia coli Journal of Molecular Biology. 133: 189-197. PMID 393832 DOI: 10.1016/0022-2836(79)90258-4 |
0.493 |
|
| 1978 |
Wu AM, Platt T. Transcription termination: Nucleotide sequence at 3' end of tryptophan operon in Escherichia coli Proceedings of the National Academy of Sciences of the United States of America. 75: 5442-5446. PMID 364481 DOI: 10.1073/Pnas.75.11.5442 |
0.516 |
|
| Show low-probability matches. |
